BioSpace News Archive

Genomind®, the leading mental health company bringing precision medicine into mainstream mental health treatment, and Jewel-Osco have expanded their partnership to provide patients with increased access to pharmacogenetic testing for mental health conditions.

Ligand Pharmaceuticals Incorporated announces that scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured.

Advarra, the premier provider of institutional review board, institutional biosafety committee, research quality and compliance consulting services, and standards-based research technology solutions from Forte, now part of Advarra, has announced the cancellation of its 2020 Spring Onsemble Conference for clinical research operations, scheduled for March 16-19.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that BioPub recently hosted an interview by Dr. KSS of the Company’s CEO and CSO.

zEEG is a Comfortable, No-Residue, Wireless EEG Headset Approved by FDA for Clinical Use

More than two-thirds of healthcare leaders have seen quality improve, but budget is the No. 1 reason they won’t invest

Behavioral health care professionals from across the country will come together on Capitol Hill this week to urge members of Congress to support the bipartisan Excellence in Mental Health and Addiction Treatment Expansion Act, which looks to extend and expand Certified Community Behavioral Health Clinics for two years and add 11 states before the demonstration expires on May 22.

George Health will receive $35 million from three major investment partners to develop drug treatments and technologies for world’s biggest killers

Catalyst Pharmaceuticals, Inc. announced that it will release fourth quarter and year end 2019 financial results after market close on Monday, March 16, 2020.

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019.